Beijing Hotgen Biotech Co., Ltd. (688068.SH) announced its third quarter report for 2025, revealing that the company achieved revenue of 310 million yuan in the first three quarters, a year-over-year decline of 19.8%. The net loss attributable to shareholders was 109 million yuan, with a non-GAAP net loss of 148 million yuan. The basic earnings per share stood at -1.23 yuan.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments